Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
DOI10.1038/S41591-022-01789-0WikidataQ112693484 ScholiaQ112693484MaRDI QIDQ94249FDOQ94249
Pier Paolo Sainaghi, Louise Warren, Sarah E Church, Katriona Goldmann, Maya H. Buch, Mattia Congia, Patrick Durez, Hasan Rizvi, Julio Ramirez, Juan D. Cañete, Vasco C. Romão, Nagui Gendi, Liliane Fossati-Jimack, Laura White, Carlomaurizio Montecucco, Alessandra Nerviani, Anna E. A. Surace, Bernard Lauwerys, Alberto Cauli, Mattia Bellan, Peter Sasieni, Sarah E. Warren, Felice Rivellese, Arti Mahto, John Isaacs, Paul M. Mckeigue, Michele Bombardieri, Robert Moots, Costantino Pitzalis, Cankut Cubuk, Gaye Hadfield, Frances Humby, Michael R. Barnes, Pauline Ho, Piero Reynolds, Briana M. Hudson, Bhaskar Dasgupta, Myles Lewis, Elisabetta Sciacca, Rebecca Hands, Joanna Peel, Arthur Pratt, Manzoor Ahmed, Christopher Holroyd, Christopher R. John, Georgina Thorborn, Chris J. Edwards, Nora Ng, Raquel Celis, Charlotte Thompson, João Eurico Cabral Da Fonseca, Edoardo Prediletto, Giovanni Giorli, Stephen Kelly, Serena Bugatti, Patrick Verschueren, Peter C. Taylor, Ernest Choy
Publication date: 19 May 2022
Published in: Nature Medicine (Search for Journal in Brave)
Cited In (1)
This page was built for publication: Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q94249)
